Trials / Completed
CompletedNCT00973960
A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Morphic Medical Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of the study is to demonstrate the safety and efficacy of the EndoBarrier Flow Restrictor in the glycemic control of diabetes in subjects with Type 2 diabetes. The primary efficacy endpoint is an assessment of glycemic control at week 24 or last assessment measured via HbA1c.
Conditions
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-06-01
- Completion
- 2010-12-01
- First posted
- 2009-09-09
- Last updated
- 2011-08-08
Locations
1 site across 1 country: Chile
Source: ClinicalTrials.gov record NCT00973960. Inclusion in this directory is not an endorsement.